Voyager Therapeutics (VYGR) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Wedbush Remains Bullish on Voyager Therapeutics (VYGR) Following 4Q Financials
March 18, 2016 8:29 AM EDTWedbush reiterated an Outperform rating and $36.00 price target on Voyager Therapeutics (NASDAQ: VYGR) following 4Q financial results.
Analyst David Nierengarten commented, "VYGR reported net income of ($8.8M), below our estimate of ($6.1M) in part due to GAAP expenses of $1.5M related to pre-IPO... More
